Filing Details

Accession Number:
0000912282-25-000059
Form Type:
13G Filing
Publication Date:
2025-01-23 19:00:00
Filed By:
Stone Daniel E.
Company:
Biondvax Pharmaceuticals Ltd.
Filing Date:
2025-01-24
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Stone Daniel E. 0 87,746 9.99%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Based on 3,411,983,584 ordinary shares outstanding as of September 30, 2024, as disclosed by the issuer on November 22, 2024. Includes 62,400 American Depositary Shares (ADSs) held directly, and 25,346 ADSs issuable upon exercise of pre-funded warrants held by RK Stone Miami LLC (RK). RK holds 646,442 pre-funded warrants, which may not be exercised if such exercise would result in beneficial ownership by RK, together with its affiliates (which include the reporting person) and certain other persons, of greater than 9.99% of the ordinary shares. Future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage.


SCHEDULE 13G


 
Stone Daniel E.
 
Signature:/s/ Daniel E. Stone
Name/Title:Stone Daniel E.
Date:01/24/2025